Sphere Bio has announced the appointment of Dale Levitzke as Chief Executive Officer, effective immediately. The leadership transition follows the retirement of Dr. Frank F. Craig, who has served as CEO since co-founding the company in 2010.
Levitzke brings over 25 years of experience across the life science tools, biotechnology, and biopharma sectors. Prior to joining Sphere Bio, he held senior leadership roles at companies including Vizgen, Dropworks Inc., NanoString Technologies, Illumina, and Helixis. His previous responsibilities included building commercial infrastructures, scaling global operations, and contributing to successful exits, including the acquisition of Dropworks by Bio-Rad for $125 million.
At Sphere Bio, Levitzke is expected to focus on expanding the company’s global commercial footprint and advancing its strategic growth initiatives. The company develops microfluidics-based platforms for single-cell analysis and picodroplet technology, with applications across biologics discovery, cell therapy, and synthetic biology.
Founded in Cambridge, Sphere Bio has built a client base of over 400 international customers, including partnerships with seven of the world’s top 10 pharmaceutical companies. The company holds more than 135 international patents and has raised over £40 million in funding to date.
Outgoing CEO Dr. Craig co-founded Sphere Bio alongside Professors Chris Abell and Wilhelm Huck, playing a key role in the company’s technology development and commercialization. Under his leadership, Sphere Bio established itself within the life science tools sector and expanded into multiple high-growth markets.
The leadership transition comes as Sphere Bio positions itself for its next phase of commercial development and potential exit.
